Impact of First-Line Therapy on Long-Term Outcomes in nAMD and DME

Now Viewing

EP: 1.Impact of First-Line Therapy on Long-Term Outcomes in nAMD and DME

EP: 2.Choosing First-Line Therapy in nAMD or DME

EP: 3.When to Switch to More Efficacious Agents

EP: 4.Real-World Experiences With Faricimab

EP: 5.Real-World Experiences With Aflibercept 8mg

EP: 6.Efficacy and Durability: New Therapies vs Aflibercept 2mg

EP: 7.Perspectives on Retinal Fluid Management

EP: 8.Perspectives on Loading Dose Recommendations for New Therapies

EP: 9.Safety Considerations for New Therapies

EP: 10.The Impact of Biosimilars in Retinal Diseases

EP: 11.The Status of Gene Therapy Development for Retinal Diseases

EP: 12.Considering Safety of Gene Therapy for Retinal Diseases

EP: 13.Role of Tyrosine Kinase Inhibitors and Gene Therapy in Retinal Diseases

EP: 14.Perspectives on the Future of Retinal Disease Management

Summary

In this series, esteemed panelists David Eichenbaum, MD Diana Do, MD Kenny Fan, MD, MBA, Seenu Hariprasad, MD, and David Brown, MD discusses the impact of novel therapies in retinal disease management. Experts discuss the evolving landscape of retinal disease treatment, focusing on the impact of first-line therapy and its impact on long-term disease progression. Kenny Fan, MD, MBA emphasizes the significance of optimizing first-line therapy to achieve the best outcomes for patients. The discussion emphasizes the critical role of timely fluid removal, while reducing fluid fluctuations, in enhancing patient overall quality of life.

This summary was AI-generated and edited for clarity.